220 related articles for article (PubMed ID: 12653924)
21. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
23. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
Tamer F; Gulekon A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):716-718. PubMed ID: 34102787
[TBL] [Abstract][Full Text] [Related]
24. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Steinhoff M; Beyer M; Roewert-Huber J; Lukowsky A; Assaf C; Sterry W
J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S88-91. PubMed ID: 18489056
[TBL] [Abstract][Full Text] [Related]
25. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
[TBL] [Abstract][Full Text] [Related]
26. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy.
Huber MA; Kunzi-Rapp K; Staib G; Scharffetter-Kochanek K
J Am Acad Dermatol; 2004 Mar; 50(3):475-6. PubMed ID: 14988696
[No Abstract] [Full Text] [Related]
27. [Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA].
Wirtz M; Helbig D
Hautarzt; 2014 Apr; 65(4):274-6. PubMed ID: 24671704
[TBL] [Abstract][Full Text] [Related]
28. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
29. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
30. Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later.
Ramachandran V; Park KE; Duvic M
Int J Dermatol; 2019 Nov; 58(11):e221-e222. PubMed ID: 31209865
[No Abstract] [Full Text] [Related]
31. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas.
Gregoriou S; Rigopoulos D; Stamou C; Nikolaou V; Kontochristopoulos G
J Cutan Med Surg; 2013; 17(1):52-4. PubMed ID: 23364151
[TBL] [Abstract][Full Text] [Related]
32. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides.
Michaelis S; Cozzio A; Kempf W; Graf P; Burg G; Dummer R
Dermatology; 2004; 209(1):72-4. PubMed ID: 15237276
[No Abstract] [Full Text] [Related]
33. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
35. Treatment of refractory stage IV mycosis fungoides with bexarotene monotherapy.
Otremba B
Dermatol Clin; 2008 Jan; 26 Suppl 1():51-2. PubMed ID: 18405188
[No Abstract] [Full Text] [Related]
36. Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States.
Xia FD; Ferket BS; Huang V; Stern RS; Wu PA
J Am Acad Dermatol; 2019 Feb; 80(2):485-492.e4. PubMed ID: 30081119
[TBL] [Abstract][Full Text] [Related]
37. Juvenile mycosis fungoides treated with bexarotene and PUVA.
Rodríguez-Vázquez M; García-Arpa M; González-García J
Int J Dermatol; 2007 Jan; 46(1):99-102. PubMed ID: 17214731
[TBL] [Abstract][Full Text] [Related]
38. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.
Ortiz-Romero PL; Maroñas Jiménez L; Muniesa C; Estrach T; Servitje O; Fernández-de-Misa R; Gallardo F; Sanmartín O; Riveiro-Falkenbach E; García-Díaz N; Vega R; Lora D; Postigo C; Jiménez B; Sánchez-Beato M; Pedro Vaqué J; Rodríguez Peralto JL; de la Cámara AG; de la Cruz J; Piris Pinilla MÁ
Lancet Haematol; 2022 Jun; 9(6):e425-e433. PubMed ID: 35654076
[TBL] [Abstract][Full Text] [Related]
39. Folliculotropic mycosis fungoides responding to bexarotene gel.
Walling HW; Swick BL; Gerami P; Scupham RK
J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]